Login / Signup

Mealtime fast-acting insulin aspart versus insulin aspart for controlling postprandial hyperglycaemia in people with insulin-resistant Type 2 diabetes.

Keith BoweringJ HarveyJ W KolaczynskiJ W SnyderB W Bode
Published in: Diabetic medicine : a journal of the British Diabetic Association (2018)
Fast-acting insulin aspart may hold promise as a more effective treatment compared with insulin aspart for controlling PPG in people with insulin-resistant Type 2 diabetes.
Keyphrases
  • type diabetes
  • glycemic control
  • cardiovascular disease
  • insulin resistance
  • metabolic syndrome
  • blood pressure
  • adipose tissue
  • deep learning